Conclusions: After adjustment for baseline characteristics, patients with symptomatic peripheral artery disease (PAD) based on prior revascularization, rather than an abnormal ABI, had a higher rate of myocardial infarction (MI) and acute limb ischemia but with a similar composite rate of cardiovascular death, MI and stroke. No significant difference was found between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb ischemic events.
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Summary: The EUCLID trial (Examining Use of Ticagrelor vs Clopidogrel In PAD) randomized 13, 885 patients with peripheral artery disease to treatment with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. Patients were enrolled based on an abnormal ankle-brachial index #0.80 or a previous lower extremity revascularization. This analysis focuses on the 7875 (57%) patients enrolled based on the previous lower extremity revascularization criterion. Important exclusion criteria were that patients could not be enrolled within 30 days of most recent revascularization nor if on dual antiplatelet therapy. The primary efficacy end point was a composite rate of cardiovascular death, MI, or ischemic stroke. The primary safety end point was major bleeding. Patients with a previous revascularization had a mean age of 66 years, 73% were male, and the median baseline ankle-brachial index was 0.78. When compared to those entered into the study based on ABI criteria, there was a lower % of women (27% vs 29.3%; P ¼ .004) but higher % of carotid stenosis (19% vs 15.3%; P ¼ .001), prior coronary intervention (26.3% vs 19.1%; P ¼ .001), and multilevel vascular disease (46.2% vs 40.7%; P ¼ .001). They were more commonly smokers, hyperlipidemia and more were being treated with cardioprotective medications (antiplatelets, statins) prior to enrollment. There were fewer diabetics in this group. 31.3% were asymptomatic while 4.5% were experiencing critical limb ischemia. 63.5% had endovascular revascularization while 36.3% required an open operation. The timing of most recent revascularization was nearly a third of patients in each of three time intervals: <6 months, 6-24 months, and >2 years. 7.5% of patients had prior amputation; 1.7% above knee, 1.1% below knee and the remainder less extensive. Compared with patients enrolled based on the ABI criterion, patients enrolled based previous revascularization had higher rates of the primary composite end point (11.4% vs 9.9%; P ¼ .02), myocardial infarction (5.9% vs 3.6%; P < .001), acute limb ischemia (2.5% vs 0.6%; P < .001), and major bleeding (1.8% vs 1.3%; P ¼ .01). After adjustment for baseline characteristics, patients enrolled based on previous revascularization vs those with abnormal ABI criteria had similar rates of the primary composite end point (P ¼ .12) but significantly higher rates of myocardial infarction (P ¼ .005) and acute limb ischemia (P < .001). Ticagrelor was not found to statistically improve the rates of primary or secondary efficacy or primary safety end points vs clopidogrel treatment: primary efficacy end point (11.4% vs 11.3%; P ¼ .90), all-cause mortality (9.2% vs 9.2%; P ¼ .93), acute limb ischemia (2.5% vs 2.5%; P ¼ .84), or major bleeding (1.9% vs 1.8%; P ¼ .41). The bleeding rate was no different for intracranial bleeds (both 0.6%), fatal bleeds (0.1% ticagrelor vs 0.3% clopidogrel) or minor bleeds (1.6% ticagrelor vs 1.3% clopidogrel). The median duration of follow-up was w30 months with 19 patients either lost to follow-up or of unknown status.
Comments: This subgroup analysis of the EUCLID study provides some insight into the care of patient with a prior revascularization. We must be more aware of the increased risk of myocardial infarction in these patients since it affects our attention and intensity of medical treatment. The increased incidence of acute limb ischemia is more difficult to interpret since we do not know the specific type of revascularization (angioplasty, bypass (synthetic or autogenous), location, etc.), which would affect the type of medical adjuvants we might chose to improve patency. The bottom-line for this study, however, is that either of these antiplatelets have a similar effect on cardiovascular risk reduction. It adds understanding to our use of monotherapy in these patients but much work needs to be done to determine optimal therapy. Conclusions: This basic science study conducted in mice demonstrates that CD98hc (a transmembrane protein involved in cell proliferation and survival and in particular the heavy chain) is required for vascular smooth muscle cell (VSMC) proliferation and that its deficiency leads to a reduced VSMC presence in the neointima. CD98hc expression in VSMC contributes to the formation of plaques that are morphologically more stable in terms of increased collagen content and reduced necrotic core area.
CD98 Regulates Vascular Smooth Muscle Cell Proliferation in Atherosclerosis
Summary: CD98 is a transmembrane protein made of two subunits e CD98 heavy chain (CD98hc) and one of six light chains e and is involved in cell proliferation and survival. However, its influence on atherosclerotic development is unknown. The aim of this study was to determine if CD98hc expression in VSMC plays a role in the morphologic make-up of atherosclerotic plaques by regulating VSMC function. The animal models were double knockout mice (SMC-specific deletion of CD98hc in an atherosclerotic prone mouse) compared to controls which were parent mice only prone to atherosclerosis. Aortic samples from these two groups were used to obtain VSMC for the culture experiments studying in vitro VSMC proliferation and apoptosis. Eight-to 10-week-old mice were placed on a high fat diet (HFD) for up to 16 weeks to aid in developing target atherosclerotic plaques and sacrificed at 0, 4, 8, 12, and 16 weeks after starting the HFD. The aortic sinus, root, and aorta were cut into 5 um sections for Oil Red-O staining (esterified lipids with microscopy), picrosirius red staining (collagen with polarized light microscopy) and immunohistochemistry. Immunohistochemistry of the aortic root sections were stained for SM22a (smooth muscle cells), MOMA-2 (macrophages) and CD98hc. Proper preparation and staining allowed quantification of the extent of atherosclerosis, presence of collagen, macrophages and smooth muscle cell infiltration into the plaque. Serum samples at start of HFD and at harvest were analyzed for serum cholesterol, triglyceride, and circulating leukocyte populations (T cells, B cells, monocytes, neutrophils). The in vivo knockout mouse study verses controls determined the effect of CD98hc deficiency on VSMC function on the atherosclerotic plaque. Eight-to 10-week-old mice from each group were placed on a HFD for 8 weeks and 3 days before sacrifice were injected with an agent taken up during proliferation. Upon sacrifice, the mouse aortas were collected, thinly sectioned, digested and divided into two for detect of proliferation or apoptosis. The culture results demonstrated dramatically reduced cell counts, cell proliferation and migration of the CD98 deficient samples when compared to controls. Analysis of aortic VSCM after 8 weeks of HFD showed a reduction in knockout mouse VSMC proliferation as well as increased apoptosis compared to controls. The long-term in vivo atherosclerosis study demonstrated that total plaque area was similar in both groups. However, the knockout mice showed reduced presence of VSMC within the plaque (2.1 6 0.4% vs 4.3 6 0.4% SM22a-positive area per plaque area; P < .05), decreased collagen content, as well as increased necrotic core area (25.8 6 1.9% vs 10.9 6 1.6%; P < .05) compared to controls. These results are consistent with the conclusions expressed.
Comments: Plaques stability is important for reduced acute rupture with local vascular occlusion and/or distal embolization. This basic science study adds one more element to our rather poor understanding of what it takes at the cellular level to achieve a stable atherosclerotic plaque. 
